Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

计划入组 172 人 · 首次发布于 2016 年 7 月 26 日

Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer

计划入组 67 人 · 首次发布于 2019 年 5 月 15 日

Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

计划入组 110 人 · 首次发布于 2021 年 2 月 4 日

Nadofaragene firadenovec-vncg(Adstiladrin)

BCG bladder cancer vaccine (Biofabri)

BCG vaccine

bioAffinity Technologies

United States

Natera

United States

Venus Concept

United States

Nadofaragene Firadenovec Shows Promise in BCG-Unresponsive Bladder Cancer, Reducing Cystectomy Rates

EMA Grants Conditional Marketing Authorization for ImmunityBio's ANKTIVA in Bladder Cancer

Phase II Study Evaluates Durvalumab for BCG-Unresponsive Bladder Cancer